Imescia is developing a new polymer prodrug technology that promotes tumor accumulation of anti-cancer drugs and preferential release within the tumor microenvironment. This technology improves anticancer drug efficacy and decreases toxicity.Our goal is to bring IMA-01 to proof of efficacy in clinical trials phase 2 by the end of 2026.

Restez informés sur l’actualité de Paris-Saclay SPRING 2019 !

* Requis